Commercial-stage biopharmaceutical company InnoCare Pharma (HKEX:09969) (SSE:688428) announced on Tuesday that it has received US Food and Drug Administration (FDA) clearance for a clinical trial of its TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332, for treating moderate-to-severe atopic dermatitis (AD).
ICP-332 demonstrated positive results in a prior China Phase II study, showing better efficacy than other AD treatments. The drug targets the JAK-STAT signalling pathway, crucial in AD development.
At present, no TYK2 inhibitors have obtained marketing approval for the treatment of AD anywhere in the world.
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
Syndax Pharmaceuticals grants share purchase inducement awards to six new employees
Hippo Pharmacy launches fast, free delivery on orders over USD150
Polarean Imaging expands reach with Taiwanese distribution deal
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
CHMP recommends EU approval of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan
Renalys Pharma completes patient enrolment for Phase III clinical trial of sparsentan
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
Roche's blood test measuring Lp(a) in molar units receives US FDA 510(k) approval
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
HeartBeam submits FDA 510(k) application for groundbreaking 12-lead ECG synthesis software
FDA grants Vicore Pharma Fast Track Designation for buloxibutid in idiopathic pulmonary fibrosis
FDA accepts Saol Therapeutics' SL1009 New Drug Application for Priority Review